Intra-CSF administration of chemotherapy medications

Michael P. Gabay, Jigisha P. Thakkar, Joan M. Stachnik, Susan K. Woelich, J. Lee Villano

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Leptomeningeal carcinomatosis is a devastating complication of cancer and is likely increasing in incidence. The combination of widespread neuro-axial spread based on CSF flow and the blood-brain barrier (BBB) has favored immediate local delivery of antineoplastic agents. With the BBB, the leptomeninges can be a sanctuary site to systemic cancers and goal of therapy includes preventing involvement in this space. Current therapies with U.S. Food and Drug Administration (FDA) approval are limited to treat hematologic cancers. Although lacking FDA guidance, a wider array of therapies is available to treat solid tumors. We provide an updated examination on both well-established intra-CSF chemotherapies as well as agents having limited data, but reports of therapeutic benefit.

Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalCancer Chemotherapy and Pharmacology
Issue number1
StatePublished - Jul 2012


  • Chemotherapy
  • Intrathecal
  • Leptomeningeal carcinomatosis
  • Neoplastic meningitis

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Intra-CSF administration of chemotherapy medications'. Together they form a unique fingerprint.

Cite this